Navigation Links
Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer

CHICAGO - June 3, 2007 - Schering-Plough Corp. announced results from a Phase III study that showed maintenance chemotherapy with Caelyx (pegylated liposomal doxorubicin hydrochloride) significantly prolonged time to progression (TTP) in patients with metastatic breast cancer with infrequent and manageable clinical toxicity after first-line chemotherapy. These data were presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology.

"While standard chemotherapy has proven effective for patients with metastatic breast cancer, their response is short-lived and the time to progression is brief," said Emilio Alba, M.D., professor at Hospital U. Virgen de la Victoria, in Malaga, Spain and lead investigator for the
study. "The results from this study showed a significantly improved time to progression (13.2 months) in patients treated with CAELYX versus the observational arm (10.2 months)."
The Spanish Cooperative Group, Grupo Espanol de Investigacion en Cancer de Mama (GEICAM) conducted the multi-center, Phase III study at seven different sites throughout Spain.

Of the 288 patients with metastatic breast cancer registered for the trial, 155 subjects who had responded to initial therapy or had stable disease were randomized either to receive CAELYX or to observation. Patients receiving therapy were given a regimen of CAELYX at 40 mg/m2 once every four weeks for 6 cycles of therapy. Patients in the CAELYX arm experienced a median improvement in time to progression of three months (13.2 months versus the observational arm of 10.2 months; p=0.0005).

The patients in the study had a median age of 57, and had adequate bone marrow, renal, hepatic and cardiac function. These patients had experienced either complete response, partial response or had stable disease. Patients received induction chemotherapy with three cycles of
anthracycline followed by three cycles of taxane, and were then randoml
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Appendicitis: Evolving Tools to Diagnose a Classic Disease
2. Non-Invasive Diagnostic Tests for Celiac Disease
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
10. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
11. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
Post Your Comments:
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... 2014 Investor-Edge has initiated coverage ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
... SAN DIEGO, Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... completed the previously announced sale of 17,857,143 shares of ... gross proceeds of approximately $5.0 million, before deducting placement ... and accredited investors participating in the offering purchased the ...
... Bionovo, Inc. (OTC Link Platform: BNVI.PK) a pharmaceutical company ... effective treatments for women,s health and cancer, announced today ... February 21, 2012 at 1:30 PM PST to discuss ... 31, 2011. (Logo:  http://photos.prnewswire.com/prnh/20111110/SF04662LOGO ) ...
Cached Medicine Technology:Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:10/25/2014)... Oct. 25, 2014 (HealthDay News) -- Arriving home safe and ... To that end, be sure that costumes and goody ... Dr. Sampson Davis, an emergency medicine doctor at Meadowlands Hospital ... carry a flashlight, and costumes should be flame-resistant, Davis said. ... plan to use makeup, test it on a small area ...
(Date:10/25/2014)... 25, 2014 TASC (Total Administrative ... other benefits account management services, announces the release ... save on taxes, reduce administrative workload, and lessen ... savings and the efficient handling of complex, time-sensitive, ... that best meets their goals and objectives. The ...
(Date:10/25/2014)... Oshkosh, Wisconsin (PRWEB) October 25, 2014 ... looking for a great selection at affordable prices. Bob ... Civic Center Huntington Center and Nationwide Arena are going ... quickly. , Click Here to browse the ... Bullet Band at QueenBeeTickets.com. , The famous singer is ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... that causes common cold sores -- herpes simplex -- might ... researchers suggest. In fact, being a carrier of certain ... disease, the researchers found. "The identification of a ... is a breakthrough," said lead researcher Dr. Hugo Lovheim, an ...
Breaking Medicine News(10 mins):Health News:Tips for Safe Trick-or-Treating 2Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3
... during pregnancy can reduce the incidence of pregnancy ... published by American Journal of Obstetrics and Gynecology. ... elevated blood pressure and proteinuria (high levels of ... hands and legs is usually seen. If left ...
... National Institute of Dental and Craniofacial Research, Marquette ... Center for Disease Control, and the National Center ... towards achieving the "Healthy People 2010 Oral Health ... combined meeting of the American Association for Dental ...
... on the sale of the soft drinks stating that it ... round the corner, there is// every possibility of children opting ... drinks has bad affects on the health of schoolchildren, specially ... the sale of these aerated drinks in government-run schools," Ghanshyam ...
... in reducing the bad cholesterol. For example food like oat ... that by combining these food substances one can get the ... they are at a higher risk of getting a heart ... (LDL) as effectively as a commonly prescribed medication. ...
... Smithkline (Britain's biggest drug manufacturer) is being registered for ... vaccine would be marketed for commercial use, by the ... similar vaccine produced by the US pharmaceuticals giant Merck ... It has been proposed to register Cervarix in the ...
... been taken into police custody after a patient died ... named, was hauled up for questioning// after a grandfather ... ,60-year-old Alan Dunn, a resident of Ferryhill, County ... he had apparently stabbed himself was removed from his ...
Cached Medicine News:Health News:Choose Foods That Keep Bad Cholesterol at Bay 2
... Mini Step™ device components are supplied sterile. , ... System is supplied sterile in 2/3, 5, 7/8, ... configurations and combinations. They are used in conjunction ... the Step™ radially Expandable Sleeve. The 5, 7/8, ...
... contains an internal seal to prevent gas leakage ... of pneumoperitoneum. The 5 mm PLUS system includes ... mm - 12 mm as appropriate and is ... of the trocar to allow insertion of smaller ...
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
... SPRING-GRIP™ single use nonconductive anchoring devices are ... mm and 12 mm sizes for use ... mm, 5 mm-10 mm, 5 mm-11 mm, ... sizes for use with the VERSAPORT™, SURGISPIKE™, ...
Medicine Products: